Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 2% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 66 | 3,318 | 37% |
| 2020 | 43 | 2,889 | 40% |
| 2021 | 39 | 2,919 | 43% |
| 2022 | 38 | 2,606 | 46% |
| 2023 | 31 | 2,623 | 50% |
| 2024 | 31 | 2,536 | 54% |
| 2025 from claims | – | 2,494 2,284–2,646 | 54% |
| 2026 forecast | – | 2,526 2,223–2,903 | 54% |
| 2027 forecast | – | 2,528 2,162–2,998 | 55% |
| 2028 forecast | – | 2,529 2,111–3,079 | 56% |
| 2029 forecast | – | 2,529 2,067–3,152 | 57% |
| 2030 forecast | – | 2,529 2,027–3,218 | 57% |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 47% of the cases CMS names in Washington; 23 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 47% inpatient hospital, 51% hospital outpatient, 2% surgery center.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~2,500 | ~1,200 | ~1,300 | ~42 |
| 2027 · ~2,500 | ~1,200 | ~1,300 | ~39 |
| 2028 · ~2,500 | ~1,200 | ~1,300 | ~38 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 48% (47% in 2025), hospital outpatient about 50% (51% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 221 | 10,948−2.9%/yr | −2.9%/yr | 3.4 | 2% | 12,000 in 2030+1.6%/yr |
| Arizona | 74 | 3,271−3.4%/yr | −3.4%/yr | 4.5 | 5% | 3,370 in 2030+0.5%/yr |
| Colorado | 18 | 1,875−3.3%/yr | −3.3%/yr | 4.0 | 3% | 2,190 in 2030+2.6%/yr |
| Oregon | 12 | 1,425−5%/yr | −5%/yr | 3.5 | 1% | 1,680 in 2030+2.8%/yr |
| Nevada | 21 | 1,084−2.7%/yr | −2.7%/yr | 3.9 | 0% | 1,250 in 2030+2.4%/yr |
| Utah | 13 | 934−6.3%/yr | −6.3%/yr | 4.4 | 2% | 1,120 in 2030+3%/yr |
| Idaho | 14 | 837−2.1%/yr | −2.1%/yr | 4.2 | 0% | 1,120 in 2030+5%/yr |
| New Mexico | 9 | 691−7.2%/yr | −7.2%/yr | 3.1 | 0% | 810 in 2030+2.8%/yr |
| Montana | 9 | 673−5.3%/yr | −5.3%/yr | 3.6 | 2% | 720 in 2030+1.2%/yr |
| Alaska | 3 | 337−1.1%/yr | −1.1%/yr | 2.8 | 0% | 420 in 2030+3.8%/yr |
| Wyoming | 4 | 320−5.8%/yr | −5.8%/yr | 3.0 | 6% | 360 in 2030+1.8%/yr |
| Hawaii | 2 | 270−2.9%/yr | −2.9%/yr | 2.2 | 0% | 360 in 2030+4.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 50 | 3,777−3.9%/yr | −3.9%/yr | 5.20.9× | 11% | 3,840 in 2030+0.3%/yr |
| Colorectal resection | 4 | 997−5.1%/yr | −5.1%/yr | 1.31.0× | 0% | 950 in 2030−0.9%/yr |
| Antireflux & hiatal hernia surgery | 11 | 474−1.1%/yr | −1.1%/yr | 0.61.0× | 0% | 630 in 2030+4.8%/yr |
| Breast reconstruction | 0 | 294−8.8%/yr | −8.8%/yr | 0.41.0× | 22% | 290 in 2030−0.1%/yr |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
CONMED leads with 33% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 8 companies reported engagement with Washington’s surgeons worth $14K in consulting, speaking, meals and travel tied to these products, about $441 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 32 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.